Piloting Your Nanovehicle to Overcome Biological Barriers.
Designing an effective nanoparticle for selective drug transport requires careful consideration of the complex biological barriers encountered in transit to the desired target. Here, we review several of these barriers, and provide possible methods for formulating liposomal nanoparticles to overcome them. The methods include the biotinylation of an antibody, and subsequent conjugation to a PEGylated cationic lipid nanoparticle. Additionally, the incorporation of drug, and other relevant characteristics of the nanoparticle are also discussed.
Department of Pharmaceutical Sciences, MCPHS University, 19 Foster Street, Worcester, MA, 01608, USA.
Steven M
SM
Richards
Department of Pharmaceutical Sciences, MCPHS University, 19 Foster Street, Worcester, MA, 01608, USA. Robert.campbell@mcphs.edu.
Robert B
RB
Campbell
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000737:chemistry; D004337:Drug Carriers / Q000737:chemistry; D004339:Drug Compounding; D016503:Drug Delivery Systems; D008081:Liposomes; D053758:Nanoparticles / Q000737:chemistry
D000911:Antibodies, Monoclonal; D004337:Drug Carriers; D008081:Liposomes
Angiogenesis; Barriers; Bevacizumab; Drug carriers; Drug delivery systems; Drug resistance; Liposomes; Nanoparticles